AxoGen (NASDAQ:AXGN) Director Amy Mcbride Wendell Sells 1,647 Shares of Stock

AxoGen, Inc. (NASDAQ:AXGN) Director Amy Mcbride Wendell sold 1,647 shares of the stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $42.60, for a total value of $70,162.20. Following the transaction, the director directly owned 93,826 shares of the company’s stock, valued at approximately $3,996,987.60. This trade represents a 1.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

AxoGen Stock Performance

Shares of AXGN opened at $40.93 on Wednesday. AxoGen, Inc. has a 52-week low of $9.22 and a 52-week high of $45.83. The company has a market capitalization of $2.18 billion, a PE ratio of -63.95 and a beta of 1.17. The company has a 50-day simple moving average of $34.78 and a 200-day simple moving average of $31.66. The company has a quick ratio of 5.33, a current ratio of 7.10 and a debt-to-equity ratio of 0.08.

AxoGen (NASDAQ:AXGN) last released its quarterly earnings data on Tuesday, April 28th. The medical equipment provider reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.12 by ($0.05). AxoGen had a negative net margin of 13.21% and a negative return on equity of 9.63%. The firm had revenue of $61.46 million during the quarter, compared to analysts’ expectations of $57.85 million. Equities research analysts predict that AxoGen, Inc. will post -0.3 earnings per share for the current fiscal year.

Institutional Trading of AxoGen

Institutional investors have recently modified their holdings of the company. MCF Advisors LLC bought a new stake in shares of AxoGen in the 4th quarter worth approximately $30,000. Aquatic Capital Management LLC raised its position in AxoGen by 287.8% during the third quarter. Aquatic Capital Management LLC now owns 1,710 shares of the medical equipment provider’s stock valued at $31,000 after buying an additional 1,269 shares during the period. Arax Advisory Partners increased its stake in AxoGen by 362.4% in the 4th quarter. Arax Advisory Partners now owns 1,045 shares of the medical equipment provider’s stock valued at $34,000 after buying an additional 819 shares during the period. Caitong International Asset Management Co. Ltd acquired a new position in AxoGen in the 4th quarter valued at approximately $36,000. Finally, Kestra Advisory Services LLC acquired a new position in AxoGen in the 4th quarter worth about $39,000. Institutional investors and hedge funds own 80.29% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. Canaccord Genuity Group lifted their price objective on AxoGen from $45.00 to $50.00 and gave the company a “buy” rating in a research report on Wednesday, April 29th. Citizens Jmp boosted their price objective on shares of AxoGen from $42.00 to $50.00 and gave the stock a “market outperform” rating in a research note on Wednesday, April 29th. Wall Street Zen downgraded AxoGen from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Lake Street Capital lifted their price target on shares of AxoGen from $40.00 to $50.00 and gave the stock a “buy” rating in a research note on Thursday, April 23rd. Finally, Zacks Research cut shares of AxoGen from a “hold” rating to a “strong sell” rating in a report on Monday, April 27th. Nine analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $46.50.

AxoGen Company Profile

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.